Company Overview of Agency for Science, Technology and Research
Agency for Science, Technology and Research provides economic oriented research to advance scientific discovery and develop innovative technology in Singapore. The company provides research services in the areas of biomedical sciences, including cancer genetics, stem cells and regenerative medicine, infectious disease and immunology, metabolic diseases, molecular cell and development biology, biomedical engineering, and platform technologies; and physical sciences and engineering, such as computational and device technologies, materials, chemistry, mechatronics and automation, manufacturing technology, metrology, and biotechnology, as well as information, communications, and media. It also o...
1 Fusionopolis Way
#20-10 Connexis North Tower
Founded in 1990
Key Executives for Agency for Science, Technology and Research
Managing Director and Executive Director
Chief Scientist and Director of p53 Lab
Deputy Managing Director of Corporate & Legal and General Counsel
Chairman of Biomedical Research Council and Director
Executive Chairman of Exploit Technologies Pte Ltd
Compensation as of Fiscal Year 2015.
Agency for Science, Technology and Research Key Developments
Agency for Science, Technology and Research Appoints Tatsumi Yamazaki to its Board
Jan 29 16
The Ministry of Trade and Industry (MTI) announced board changes at Agency for Science, Technology and Research (A*STAR). MTI has appointed Tatsumi Yamazaki, Distinguished Advisor, Chugai Pharmaceutical Co. Ltd. to the Board of A*STAR.
Applied Materials, Inc. and Agency for Science, Technology and Research Announce New R&D Joint Lab in Singapore for Advanced Semiconductor Technology
Oct 18 15
Applied Materials, Inc. announced it plans to establish a new R&D laboratory in Singapore in collaboration with the Agency for Science, Technology and Research (A*STAR). The SGD 150 million joint investment will focus on developing advanced semiconductor technology to fabricate future generations of logic and memory chips. The SGD 150 million joint lab will be housed within A*STAR's new R&D cluster at Fusionopolis Two and will feature a 400 square meter Class 1 cleanroom with semiconductor process equipment that has been custom designed and built by Applied Materials. The facility will be staffed by 60 highly skilled researchers and scientists, working together with extended research teams at A*STAR's other research institutes. The joint lab combines Applied Materials' expertise in materials engineering with A*STAR's multi-disciplinary R&D capabilities. A*STAR's Institute of Microelectronics (IME), Institute of Materials Research and Engineering (IMRE), and Institute of High Performance Computing (IHPC) will contribute to research in low-defect processing, ultra-thin film materials, materials analysis and characterization, and modeling and simulation in many areas. The joint lab is also supported by The Singapore Economic Development Board, and is in line with its efforts to promote R&D and advanced manufacturing activities. The intention is for products developed by the joint lab to be manufactured by Applied Materials in Singapore. In addition, Applied Materials plans to conduct experiments on the synchrotron at the Singapore Synchrotron Light Source (SSLS) and work with the National University of Singapore where a new beamline for semiconductor applications is to be developed. Funding for the construction of the new beamline is supported by the National Research Foundation.
Visterra Partners with Agency for Science, Technology and Research to Develop VIS513
May 21 15
Visterra, Inc. and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research, Singapore announced a collaboration to further the development of VIS513, Visterra's broadly neutralizing antibody for the treatment of dengue fever. VIS513, which was engineered using Visterra's innovative and proprietary technology, is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. The company's preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. The collaboration combines Visterra's expertise in therapeutic antibodies for challenging infectious diseases with D3's proficiency in bringing early stage discoveries into clinical development. D3 and Visterra will also work together with infectious disease experts at Duke-National University of Singapore (Duke-NUS) to generate additional data necessary to initiate clinical trials of VIS513. Upon completion of these activities, D3 and Visterra will advance VIS513 through proof-of-concept clinical trials in humans, which will be conducted in Singapore. Under the terms of the collaboration agreement Visterra retains all rights to develop and commercialize VIS513 globally.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|